Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion

[dreamer042]

Key Points

• Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion.
• AtaiBeckley is developing several psychedelics for mental health conditions.
• The deal gives Lilly access to experimental drugs based on DMT and MDMA.
  
  Eli Lillywill acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum grows for using versions of the drugs as mental health treatments.
  
  The transaction gives Lilly access to AtaiBeckley’s experimental DMT-based drug that’s being studied in Phase 3 clinical trials for treatment-resistant depression. AtaiBeckley is developing several other psychedelics for mental health conditions, including one related to MDMA, also known as ecstasy.
  
  AtaiBeckley’s lead drug, BPL-003, is related to dimethyltryptamine, or DMT. The nasal spray is administered in a clinic where patients are monitored for about two hours. Initial Phase 3 trial results are expected in 2029.
  
  “The goal here was to find a different type of medicine that could help them, not just changing the neurotransmitters in their brain, but actually changing the connections of neurons in their brain to try and help them from the disease,” Lilly’s chief scientific officer, Dan Skovronsky, said Thursday in an interview with CNBC.
  
  He said the team at AtaiBeckley found the drug could have a profound effect very quickly that could persist for months, making BPL-003 a “very different type of medicine for treating depression.” It’s possible that people could receive the treatment a couple times a year, Skovronsky said.
  
  The acquisition price of $6.75 per share in cash, or about $2.8 billion, is 26% higher than AtaiBeckley’s Wednesday close of $5.36 per share. Lilly could pay up to an additional $2.50 per share, or $1 billion, if the company’s drugs meet certain development and regulatory milestones.
  
  The deal marks the latest sign of momentum behind psychedelics. The Trump administration has prioritized development of psychedelic-based treatments for mental health conditions, including depression and post-traumatic stress disorder.
  
  Lilly has a long history in mental health. Its blockbuster antidepressant Prozac transformed the treatment of depression and fueled Lilly’s last major sales boom before the GLP-1 explosion. Skovronsky said when Lilly started working in the area, there was stigma around treating depression at all. He compared that to some of the resistance to psychedelics now and said that actually attracts him to the space.
  
  Where Prozac and similar drugs slowly change the chemicals in the brain, psychedelics may quickly prompt neurons to create new connections. Emerging research suggests people with treatment-resistant depression may not have enough plasticity in the brain, and these experimental drugs try to change that.
  
  “We understand now the different receptors in the brain that drugs like this bind to, and we understand that those receptors have a signaling cascade inside of neurons that then tells them to become more plastic,” Skovronsky said. “Now, is that related to the hallucinogenic experience, or are those two things dissociated? I think the field debates that now, but for now, we have a medicine that causes both, and as a result, I think has this really important treatment effect.”
  
  It’s also the latest deal for Lilly, which has been on a spending spree. Before announcing its intention to acquire AtaiBeckley, Lilly had already said it would spend more than $10 billion up front and potentially up to $25 billion on eight acquisitions this year.
  
  The drugmaker has deliberately targeted later stage and therefore more expensive deals than it has historically pursued as it settles into its status as the world’s most valuable healthcare company.
  
  “If we see great ideas that we think we can use to help people that need them, of course we’ll do deals,” Skovronsky said.
  
  AtaiBeckley shares spiked more than 30% in morning trading following the announcement.
  

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

 

[stuartroelke]

Saw this posted on Reddit recently—would love to be in those studies.

Lots of folks over there were worried about patents, but they fail to realize that legalization would nullify all concern. If psychedelics were legal—as they should be—then patents eventually lose power. Facilitators could continue fundraising via donations or gifts without violating laws, even if there was eventually some overlap in practices.

 

[aizoaceous]

Lots of folks over there were worried about patents, but they fail to realize that legalization would nullify all concern.

I'm not sure what kind of legalization you're thinking? AtaiBeckley's goal is almost certainly to bring these drugs to market as patented controlled substances, similar to Spravato for ketamine. Possession without a prescription would remain a criminal offense. The price would be set in negotiation with insurance companies, and to justify their valuation must be high.

This is good news for anyone hoping to consume these substances under the supervision of an MD or other DEA-licensed practitioner, but otherwise neutral news at best. It's potentially bad news otherwise, to the extent that AtaiBeckley has incentive to oppose Colorado-style decriminalization (since that wouldn't be restricted to their patented formulation, and thus removes that monopoly) and the resources to lobby accordingly.

Note that BPL-003 is 5-MeO-DMT, which the media report unfortunately conflates with DMT. There is no particular reason to expect that BPL-003 performs better than or differently from the nasal sprays that people on this forum (including me) have compounded in their sheds, but a new salt or polymorph is considered novel by the patent system despite typically being straightforward to discover. I wonder how many new pharmaceutical salts were first reported on this forum; I'm pretty sure my mesembrine malate was, and there must be others.

I wonder how things are going at the Usona Institute. They also have a trial, of 5-MeO-DMT succinate by intramuscular injection. I don't believe they've filed any patents, presumably since they're organized as a nonprofit and thus happy to let generic makers bring it to market at nominal cost.

 

[_Trip_]

With all our experimenting here at nexus i don't know why we don't post our salt discoveries online including lab data and their abilities to dissolve in say saline for pharmaceutical purposes. It would technically beat any future company to apply for a patent as there is documented public knowledge I.e proof of prior art.

It could future safe guard these molecules (salt forms). Ofcourse we can always fall back on its natural occuring form as nature can't be patented.

 

[new_science]

_Trip_, you must be aware that The Traveler helps to operate Home, which is for that exact purpose!

EDIT: Not sure why the hyperlink named itself Home, it links to Porta Sophia.

 

[Jamie01]

Lilly is an immoral company and should have been non existent after they got sued the first time. Screw Eli Lilly. This company has misrepresented data before for profit, and I wouldn’t trust them to not do it again and again.

 

[Jamie01]

#09-038: Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa (2009-01-15)

For real no one needs Eli Lilly to be their drug dealer.

 

[_Trip_]

_Trip_, you must be aware that The Traveler helps to operate Home, which is for that exact purpose!

EDIT: Not sure why the hyperlink named itself Home, it links to Porta Sophia.

Haha I was actually not aware, I feel silly.

 

[stuartroelke]

I'm not sure what kind of legalization you're thinking? AtaiBeckley's goal is almost certainly to bring these drugs to market as patented controlled substances, similar to Spravato for ketamine. Possession without a prescription would remain a criminal offense. The price would be set in negotiation with insurance companies, and to justify their valuation must be high.

My original comment was mainly to acknowledge misplaced concern on a different forum. Legalization of entheogens in general could reduce dependence on patented variations, and may also eliminate some of the unnecessary divisiveness that currently dissuades folks from accessing natural forms of these medicines.

With all our experimenting here at nexus i don't know why we don't post our salt discoveries online including lab data and their abilities to dissolve in say saline for pharmaceutical purposes. It would technically beat any future company to apply for a patent as there is documented public knowledge I.e proof of prior art.

Precisely. Though, publicly disseminating information (mostly practices and procedures) beats the game in some ways.

 

[blig-blug]

Legalization of entheogens in general could reduce dependence on patented variations

Yes, so expect those that are hoping to profit from their bogus patents to fight against it tooth and nail.

If psychedelics get eventually approved for medical use, I expect to see all these people in the so-called "Psychedelic Renaissance" suddenly turn from uncritical promotion of psychedelics to uncritical exaggeration of their dangers "outside of proper clinical supervision".

I expect a lot of psychedelics users (although probably not in the Nexus) to fall for whatever trick they try, as for many the "Psychedelic Renaissance" propaganda and milieu is basically gospel.

 

[Jamie01]

I can’t stand the term “psychedelic renaissance”.

A lot of this stuff involving psychedelics and money in general makes me want to gag and give up on the whole scene. I think I’d rather just deal with life without tripping than have the whole thing as an $ pre fabricated supervised package. How “safe”.